
### Considerations for Implementing Tests Approved by Another National Regulatory Authority

2nd International Workshop Accessible and Quality Assured In Vitro Diagnostic Tests for Public Health Programs November 20, 2012 Elliot P. Cowan, Ph.D.

### Disclaimer

• This presentation reflects the views of the presenter and should not be construed to represent FDA's views or policies.

### **Considering Tests Approved by an NRA**



$$\begin{split} R &= \rho^{l} e^{-\frac{1}{2}\rho} H(\rho) \\ R' &= \left(\frac{l}{\rho} - \frac{1}{2}\right) R + \rho^{l} e^{-\frac{1}{2}\rho} H' \\ \rho^{2} R' &= \left( O N^{2} S T A^{2} N^{2} N^{2} S T A^{2} N^{2} S T A^{2} N^{2} S T A^{2} N^{2} S T A^{2} N^{2} N^{2} N^{2} S T A^{2} N^{2} N^{2} N^{2} S T A^{2} N^{2} N^{2}$$

# Constants? Design and Manufacturing

- Product description
- Product design
- Design overview
- Formulation and composition
- Biological safety
- Key suppliers

- Documentation of design changes
- Manufacturing
  process
- Overview of manufacture
- Site of manufacture

### **Constants?** Product Performance

- Analytical studies
- Specimen types
- Analytical performance characteristics
- Accuracy of measurement
- Analytical sensitivity

- Analytical specificity
- Metrological traceability of calibrators and control material values
- Measuring range of assay
- Validation of assay cutoff
- Software verification and validation

### Constants? Other

- Commercial history (countries of supply)
- Quality Management System
  - Quality manual
  - Quality management system documents
- Inspection

$$\begin{split} R &= \rho^{l} e^{-\frac{1}{2}\rho} H(\rho) \\ R' &= \left(\frac{l}{\rho} - \frac{1}{2}\right) R + \rho^{l} e^{-\frac{1}{2}\rho} H' \\ \rho^{2} R' &= \sqrt{\rho} A^{\frac{1}{2}} R^{2} R + \rho^{l} e^{-\frac{1}{2}\rho} R^{2} R' \\ (\rho^{2} R')' &= (l-\rho) R + \left(l\rho - \frac{1}{2}\rho^{2}\right) \left[\left(\frac{l}{\rho} - \frac{1}{2}\right) R + \rho^{l} e^{-\frac{1}{2}\rho} H'\right] \\ &+ \left(\frac{l+2}{\rho} - \frac{1}{2}\right) \rho^{l+2} e^{-\frac{1}{2}\rho} H' + \rho^{l+2} e^{-\frac{1}{2}\rho} H'' \\ \frac{\frac{1}{\rho^{2}} (\rho^{2} R')'}{\rho^{l} e^{-\frac{1}{2}\rho}} &= \left(\frac{l}{\rho^{2}} - \frac{1}{\rho}\right) H + \left(\frac{l}{\rho} - \frac{1}{2}\right) \left[\left(\frac{l}{\rho} - \frac{1}{2}\right) H + H'\right] \\ &+ \left(\frac{l+2}{\rho} - \frac{1}{2}\right) H' + H'' \\ &= \left[\frac{l(l+1)}{\rho^{2}} - \frac{l+1}{\rho} + \frac{1}{4}\right] H + \left[\frac{2l+2}{\rho} - 1\right] H' + H'' \end{split}$$

# Variables

- What does FDA approval/clearance of an IVD address?
  - Safety and effectiveness for marketing in the US
  - Test performance in predominantly US populations
  - Consistency of manufacturing at specific manufacturing sites
  - Test design for US users
  - Test design for US testing environments

### Variables Test Performance

- Testing in US populations
  - Population/region differences in test performance
  - Sensitivity/specificity/predictive values may vary by country/region/disease prevalence
  - Confounding factors (co-infections, environmental, other)

### Variables Manufacturing Site

- Manufacturing facility evaluated with product
- Same controls in place at manufacturing site not approved with product?
- Potential for significant impact on product performance
- Product design

### Variables Product Design

- US approved/cleared test designed for US operators and US conditions
  - Storage requirements (temperature/humidity) and stability
  - Instructions for use
  - Trained personnel
- Resource-limited settings
  - Temperature and humidity outside of validated range
  - Lack of trained personnel
  - Lack of special storage conditions
  - Unreliable power sources
  - Need for studies to demonstrate test shelf-life, shipping stability, etc.

# Variables Product Design, cont.

- "Regulatory versions" of products
  - Manufacturers produce different versions of the same test for use in different markets
    - Manufacturing site
    - Product quality
    - Different NRA degree of oversight
  - May lead to assumption that all tests by that name are the same

# Variables Risk

- Risk/benefit consideration may differ from region to region
- Nevertheless, it is critical for:
  - Performance parameters to be well characterized
  - -Performance to be consistent from lot to lot
  - -Labeling to be truthful

# SUMMARY

- There are elements of that evaluation by an NRA that may be taken into account by countries who adopt a test previously approved by an NRA (constants).
- However, there are also critical elements that do not necessarily transfer (variables) and should be taken into account to assure maximum public health benefit in specific settings.

### **AN ANALOGY**

### Evaluating Previously Approved Diagnostics: Reinventing the Wheel?




### Evaluating Previously Approved Diagnostics: Reinventing the Wheel?



#### **ROBUSTNESS**




















#### Where We Run into Problems...



#### Where We Run into Problems...



Limited applicability

#### Where We Run into Problems...



Inappropriate adaptation

### Ultimately leading to...



# Obrigado!